Two Johnson & Johnson Subsidiaries to Pay Over $81 Million to Resolve Allegations of Off-Label Promotion of Topamax
Two Johnson & Johnson Subsidiaries to Pay Over $81 Million
to Resolve Allegations of Off-Label Promotion of Topamax
to Resolve Allegations of Off-Label Promotion of Topamax
American pharmaceutical manufacturers Ortho-McNeil Pharmaceutical LLC and Ortho-McNeil-Janssen Pharmaceuticals Inc., both subsidiaries of Johnson & Johnson, have agreed to pay more than $81 million to resolve criminal and civil liability arising from the illegal promotion of the epilepsy drug Topamax.